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S3. What types of interventions help young people to quit
smoking in Sandwell? The views of Stop Smoking Advisors
Leisa-Kay Harris
Birmingham Community Health Care Trust
Objective: The aim of the study was to evaluate the effectiveness of
interventions that help young people to quit smoking in Sandwell
Birmingham. It is anticipated that the evidence will help to improve
knowledge and understanding of providers of similar services, which may
assist in the improvement and adjustment of practices.
Method: A qualitative method was used to address the research question. Data
was collected through ﬁlmed recordings with eight participants that formed
two focus groups with four participants in each group. The participants were
professionals from various backgrounds who all had speciﬁc roles as Stop
Smoking Advisors. The focus group discussions were run by the researcher
and took place in a room in the same building where the Stop Smoking
Advisors work in Sandwell.
Results: There is strong evidence that one-to-one interventions and peer
support are the most effective interventions that helped young people to quit
smoking in Sandwell. There are others that are promising but as yet lack a ﬁrm
evidence base such as different models and approaches. In contrast, there are
interventions that have least effectiveness, in particular motivational
interviewing, nicotine replacement therapy, groups, social marketing cam-
paigns, incentives and rewards. Added to this, Stop Smoking Advisors felt that
they would need to be provided with more training and how to adapt to the
new models. On a whole, implementing change can be challenging as there
might be issues with funding for training and some people may not want to
adopt to change.
Conﬂicts of Interest: None.
Funding: None.
Corresponding author: Leisa-Kay Harris.
Email: Leisa-Kay.Harris@hotmail.com
S4. Handgrip strength as correlate and predictor of lung
function in apparently healthy young adults
NC Mgbemena1, HA Aweto1, BA Tella1, OE Nwosu2
1Department of Physiotherapy, University of Lagos, Lagos State, Nigeria;
2Department of Physiotherapy, University of Nigeria Teaching Hospital, Ituku/
Ozalla, Enugu, Nigeria
Aim: This study determined the prediction of lung function using handgrip
strength in apparently healthy young adults.
Method: Four hundred participants (200 males and 200 females) were involved
in the study. They were apparently healthy students of the College of
Medicine, University of Lagos, Nigeria, and aged 16–30 years. Ethical approval
was obtained from the Health Research and Ethics Committee of the Lagos
University Teaching Hospital (LUTH) Idi-Araba, Lagos. The participants’
handgrip strength was assessed using the Jamar dynamometer. Selected
lung function variables (forced expiratory volume 1 [FEV1], forced vital capacity
[FVC] and peak expiratory ﬂow rate [PEFR]) were assessed using a portable
spirometer.
Results: The mean of the dominant handgrip strength in males
(38.90 ± 8.30 kgf) was higher than of the female participants
(25.80 ± 5.70 kgf). Likewise, the lung function of the male participants
(FEV1= 3.36 ± 0.57 l; FVC = 3.73 ± 0.82 l and PEFR= 7.71 ± 1.77 l/s) was higher
than the lung function of the females (FEV1 = 2.38 ± 0.36 l; FVC = 2.60 ± 0.42 l
and PEFR= 5.60 ± 1.37 l/s). There was signiﬁcant but weak correlation between
the dominant handgrip strength and lung function variables assessed in male
participants (FEV1, r= 0.284; FVC, r= 0.302; and PEFR, r= 0.180) and female
participants (FEV1, r= 0.232; FVC, r= 0.184; and PEFR, r= 0.283). The same
applied to non-dominant handgrip and lung function. Regression equations
were also proposed for predicting lung function using handgrip strength,
height, weight and age of the participants according to gender. The
regression analysis showed that handgrip strength was a signiﬁcant predictor
for all lung function parameters in all participants except for the PEFR in the
male participants.
Conclusion: Handgrip strength was a predictor for FEV1 and FVC in healthy
young adults.
Conﬂicts of Interest: None.
Funding: The Jamar dynamometer and SP 10 Spirometer were provided by
Classic Home Care, 259 West 123rd Street, New York, NY 10027.
Corresponding author: Mgbemena Mgbemena.
Email: ndeemgbemena@gmail.com
S8. Understanding shared decision making in personalised
action plan implementation in adult asthma: an exploratory
feasibility study
N Callender, V Auyeung, K Newell
Lewisham Integrated Medicines Optimisation Service (LIMOS)
Aim: Personalised asthma action plans (PAAPs) improve asthma outcomes and
reduce the likelihood of hospitalisation from acute exacerbations. Although
recommended since the 1990s, implementation is suboptimal. The barriers to
implementation are well-established, and shared decision making (SDM) is a
potential facilitator, but there is no consensus on what SDM parameters are
required for PAAP implementation. This exploratory feasibility study design
aimed to address this gap using the participant’s views to identify factors
integral to embedding SDM in PAAP implementation during asthma reviews.
www.nature.com/npjpcrm
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Method: Purposive samples of eight asthma specialists from across the UK and
three patients from a large tertiary centre were recruited. All interview data
were audio recorded. Data were thematically analysed using codes from
existing theoretical frameworks for SDM (with nine core elements) and the
implementation of evidence-based practice.
Results: Four out of nine key elements of SDM were deemed relevant to
asthma action plan implementation: (1) clarifying and checking patients’
understanding of asthma, (2) establishing patient preferences and values, (3)
discussing patients’ ability and conﬁdence to self-manage asthma, and (4)
regular follow-up. Barriers included a lack of time, restricted access to specialist
expertise, lack of support and limited continuing education. The identiﬁcation
of four elements of SDM relevant to PAAP implementation could better assist
patient involvement.
Conclusion: Multi-faceted interventions aimed at improving training, the co-
ordination of specialist asthma expertise in general practice and hospital
settings are required to overcome barriers to effective implementation. Further
research therefore is warranted to investigate barriers to partnership working
between asthma specialists and generalists through observational studies at
the clinical interface of asthma care, to establish if a supportive environment to
involve patients in decisions is created.
Conﬂicts of Interest: NC and VA have no conﬂicts of interest to declare in
relation to this article. KN is a respiratory clinical nurse specialist involved in the
service development, asthma education and training.
Funding: This work received no funding.
Corresponding author: Natasha Callender.
Email: natasha.callender1@nhs.net
S10. Efﬁcacy of Trimbows, a novel triple extraﬁne combination
treatment in chronic obstructive pulmonary disease (COPD)
patients at high risk of exacerbations: a sub-group analysis of
the TRINITY Study
M Scuri1, M Spinola1, S Vezzoli1, A Muraro1, S Petruzzelli1, J Vestbo2
1Chiesi Farmaceutici S.p.A-Parma/IT; 2University of Manchester, Manchester, UK
Aim: Free triple therapy combining an inhaled corticosteroid with a long-
acting beta-2 agonist and a long-acting muscarinic antagonist is commonly
used to treat chronic obstructive pulmonary disease (COPD). Such treatment
currently involves the use of different inhalers. This analysis aims to evaluate
the effect of a ﬁxed triple combination on COPD exacerbations in a sub-group
of patients with 41 exacerbation in the previous year.
Method: TRINITY (NCT01911364) was a phase III, double-blind, 52-week study
where 2,691 severe/very severe COPD patients with a history of exacerbations
were randomised to receive Trimbows (ﬁxed dose combination of
beclometasone dipropionate, formoterol fumarate and glycopyrronium
bromide) or Tiotropium or a ﬁxed-dose combination of beclometasone
dipropionate and formoterol fumarate (Fostairs)+Tiotropium. The primary
analysis demonstrated that Trimbows was superior to Tiotropium in reducing
moderate/severe exacerbations and comparable to the free combination of
Fostairs+Tiotropium. Here we report the analysis of the primary efﬁcacy
variable performed on the ITT population after stratifying by number of COPD
exacerbations in the 12 months before screening (1: n= 2,143 or41: n= 546).
Results: Compared to Tiotropium, Trimbows signiﬁcantly reduced exacerba-
tions in both subgroups of patients, with a more pronounced effect in patients
with41 exacerbation in the previous year (adjusted rate ratio: 0.836 [95% CI:
0.707, 0.990], P= 0.038 and 0.724 [0.551, 0.951], P= 0.020, respectively), thus
conﬁrming the results in the overall population. Compared to the free
combination, Trimbows signiﬁcantly reduced exacerbations in patients with
41 exacerbation in the previous year (adjusted rate ratio: 0.713 [0.511, 0.995],
P= 0.047), whereas in the subgroup of patients with 1 exacerbation the two
treatments had a comparable effect (adjusted rate ratio: 1.143).
Conclusion: The results of this pre-planned subgroup analysis showed that
beclometasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium
bromide (GB) (Trimbows) confers a superior clinical beneﬁt compared to
Fostairs+Tiotropium in a subgroup of COPD patients at higher risk for
exacerbations.
Acknowledgment: This abstract has been adapted from an abstract presented
at the American Thoracic Society Conference, May 2017.
Conﬂicts of Interest: M. Scuri, M. Spinola, S. Vezzoli, A. Muraro, S. Petruzzelli,
Chiesi Farmaceutici S.p.A., Parma/IT. J.Vestbo has received honoraria from
AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis.
Funding: The abstract has been funded by Chiesi Farmaceutici S.p.A.
Corresponding author: Mario Scuri.
Email: m.scuri@chiesi.com
S12. COMPARATIVE ASSESSMENT OF CARDIOPULMONARY
PARAMETERS OF PETROL STATION ATTENDANTS AND NON-
PETROL STATION ATTENDANTS
OA Ajiboye, TO Ajepe, OO Ladenika
Department of Physiotherapy, Lagos University Teaching Hospital (LUTH),
Idi-Araba, Nigeria
Aim: In many developing countries, people are still employed to dispense
Premium Motor Spirit (PMS) and other petrochemical products at automobile
re-fueling stations. They are often referred to as Petrol Station Attendants (PSA)
and are constantly exposed to the deleterious effect of inhalation of PMS
fumes, particularly on their respiratory system. This study aimed at studying
the effects of PMS fumes inhalation on the cardio-pulmonary function of PSA.
Method: The study was conducted in Surulere Local Government Area of Lagos
State, Nigeria among 165 participants; 92 PSA and 73 age and gender-
matched non-PSA. Data on demographic characteristics, duration of exposure
(working hours per day and years of working experience) selected
cardiovascular parameters (systolic blood and diastolic blood pressure and
pulse pressure) and pulmonary parameters (forced vital capacity, forced
expiratory volume in the ﬁrst second and peak expiratory ﬂow rate) were
collected in both groups. Independent T-Test was used to compare the
cardiovascular and pulmonary parameters between the two groups and was
also used to compare participants with less than 5 years and more than 5 years
working experience. Relationship between the duration of exposure and
cardiopulmonary parameters was investigated using Persons correlation
coefﬁcient. Level of signiﬁcance was Po0.05.
Results: The diastolic blood pressure was signiﬁcantly higher among PSA and
those with greater than 5 years working experience. There was a signiﬁcant
relationship between the number of working hours per day and all the
cardiovascular parameters assessed. Self-reported respiratory symptoms were
higher among PSA.
Conclusion: PSA may be prone to high blood pressure in addition to respiratory
complications. Also prolonged exposure to PMS fumes may increases the risk
of developing high blood pressure.
Conﬂicts of Interest: None.
Funding: This research did not receive any grant from funding agencies in the
public, commercial, or not-for-proﬁt sectors. It was funded collectively by the
authors.
Corresponding author: Titilope Ajepe.
Email: tobiigbari@gmail.com
S13. Improving spacer delivery for low ﬂow (paediatric) use
MJ Sanders, R Bruin, CT Tran
Clement Clarke International Limited, Harlow, CM20 2TT, UK
Aim: Choosing the best valved holding chamber (VHC) can seem complicated,
with choice inﬂuenced by recommendation, prescription status, device utility,
and patient age and lung function. Young children are the predominant users
of VHCs, mainly because they struggle to receive an effective dose owing to
the requirement to coordinate pressurised metered dose inhaler (pMDI)
actuation with the inhalation manoeuvre. For these patients, being able to
receive an effective dose via tidal breathing is very attractive.
Healthcare advice is rightly inﬂuenced by scientiﬁc evaluation. VHC
assessments are based on standardised 30 L/min ﬂow rate methodologies
not representative of paediatric tidal breathing (JAM 1997;10:341-9, https://doi.
org/10.1089/jam.1997.10.341). VHC comparisons have noted the limitations
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imposed by permanently open exhaust valves, especially in the context of low
(paediatric) ﬂows (JAMPPD 2017;30(3):A-12, https://doi.org/10.1089/jamp.2017.
ab01.abstracts). We have therefore undertaken valve technology research
aiming to improve function at low ﬂows, ensuring improved suitability for
children.
Method: The Able Spacer-2 mouthpiece/valve arrangement creates perma-
nently open exhalation ports that inevitably increases the ‘valve-open’ ﬂow
rate. 100 μg salbutamol (Ventolin Evohaler) aerosol performance (mean± SD)
at 30 l/min (Next Generation Impactor, NGI) and 10 l/min dose uniformity
(Dosage Unit Sampling Apparatus, DUSA) have been assessed against three
adjustments (A1, A2, A3) to valve cut-geometry and shape, and to exhalation
port size and valve support.
Results: NGI ﬁne particle fraction (%o5 μm) for pMDI-alone, A1, A2 and A3
were 47.9 ± 2.4, 55.0 ± 2.0, 51.8 ± 2.4 and 55.4 ± 2.5, respectively. Respective ﬁne
particle dose data (μgo5μm) were 41.7 ± 4.4, 55.8 ± 9.2, 52.2 ± 9.9 and
53.1 ± 10.3. DUSA recoveries (ug, quantifying drug retention within the VHC)
for A1, A2 and A3 were 43.6 ± 6.5, 45.1 ± 2.8, and 52.7 ± 4.5; representing
49.4 ± 6%, 56.6 ± 4% and 58.0 ± 2% of the recovered pMDI-alone emitted dose.
Conclusion: Using accepted in vitro product equivalence testing, the data
indicate the valve developments should improve drug delivery and
demonstrate improvements on previous low ﬂow, dose uniformity compara-
tor research (JAMPPD 2015;28:A-2, https://doi.org/10.1089/jamp.2015.ab02.
abstracts).
Conﬂicts of Interest: MJ Sanders and R Bruin are employees of Clement Clarke
International Limited.
Funding: Clement Clarke International Limited provided the study funding (no
grant number).
Corresponding author: Mark Sanders.
Email: msanders@clement-clarke.com
Acknowledgment: This abstract is new, but data presented at 2017 ISAM, Sante
Fe New Mexico; published Sanders, M., Bruin, R. & Tran, C. Holding chamber
valve technology: effectiveness at low ﬂow rates. J. Aerosol Med. Pulmon. Drug
Del. 30, A-21–A-22 (2017). https://doi.org/10.1089/jamp.2017.ab01.abstracts
S14. Objective assessment of inhaler technique with
Smartphone App
MJ Sanders, EA Crawford
Clement Clarke International Limited, Harlow, CM20 2TT, UK
Aim: Regular inhaler technique review is recommended in all major guidances.
Good technique requires a device-speciﬁc inhalation manoeuvre—often
concurrent with inhaler actuation—that can only be assessed subjectively. Flow
guidance whistles help (Inhalation 2015;9(3):23-24, http://www.inhalationmag.
com/Dynamic/BackPage/inh_backpage_2015_06.pdf), but remain a subjective
assessment. Currently, healthcare professionals lack the tools to conduct objective
reviews. If, however, the guidance whistle and other sounds could be analysed by
smartphone, the potential exists for objective, clinical data.
Flo-Tone R (FTR, Clement Clarke) is an add-on guidance whistle used to
illustrate/clarify Respimat inhaler technique, ﬁeld-tested in a broadly based
application by Boehringer Ingelheim, Germany. Respimat produces a slow-
moving mist of ﬁne droplets with a comparatively long 1.2-s spray duration.
Ideally the patient should inhale for this period following actuation. Clin-e-cal
Limited has created an App to recognise and record the FTR sound and
actuation ‘click’ of a placebo Respimat.
Method: Healthy volunteers (n= 25, 23–85 years, mean 41.4) completed three
inhalation manoeuvres with these tools. Two parameters were ascribed to
successful use: Respimat actuation during the ﬁrst second of inhalation and an
inhalation duration of ≥ 2.0 s following actuation.
Results: Smartphone display of activity/parameters versus time was achieved. On
attempt-1, 13 subjects (52%) actuated the device during inhalation (mean 0.65 s
into the manoeuvre), 7 actuated before inhalation, 5 after. By attempt-3, 24
subjects (96%) correctly actuated during inhalation. Those who succeeded on
attempt-1 improved mean coordination time to 0.38 s. After attempt-3, 20
subjects (80%) had extended mean post-actuation inhalation duration to 3.27 s.
Conclusion: This preliminary use of placebo Respimat using the FTR-and-App
has proved successful with volunteers. Objective data has enabled technique
improvements to be recognised. The FTR-App combination is being
developed to provide a primary care training tool. It is hoped that availability
of objective assessment tools will encourage better inhaler technique.
Conﬂicts of Interest: MJ Sanders is an employee of Clement Clarke International
Limited. MJ Sanders and EA Crawford are Directors of Clin-e-cal Limited which
designed and provide the Raﬁ-Tone App.
Funding: Clement Clarke International Limited provided study funding (no
grant number).
Corresponding author: Mark Sanders.
Email: msanders@clement-clarke.com
S18. Barriers and enablers for primary health care practitioners
when referring patients with chronic obstructive pulmonary
disease to pulmonary rehabilitation: a qualitative study
J Young1,2, R Jordan1,2, P Adab1,2, A Enocson1,2, S Greenﬁeld1,2
1University of Birmingham; 2Community Nursing, Anglia Ruskin University
Introduction: Chronic obstructive pulmonary disease (COPD) is a chronic
debilitating disease. Pulmonary rehabilitation (PR) is a cost-effective, internationally
recommended intervention for COPD patients suffering breathlessness and/or
functional limitation. Referral is predominately health care practitioner led, yet
referral numbers and patient uptake to this widely available intervention are poor.
Aims: To understand the barriers and enablers for primary health care
practitioners (PHP) when referring or considering patient referral to PR and to
explore whether patient characteristics inﬂuence the decision to refer COPD
patients’ PR.
Methods: Semi-structured interviews, underpinned by phenomenology. Questions
based on the Capability, Opportunity, Motivation, Behaviour Model (COM-B) with
PHPs across General Practices in Cambridgeshire and West Midlands. Participants
were purposively selected and asked about their experience and practice in
relation to referring COPD patients for PR. Images depicting patients with varying
COPD severity were used to stimulate memory and associative recall. Interviews
are ongoing but will continue until theme saturation.
Analysis: Interview data were recorded and transcribed. Two-level data analysis
will be undertaken: Rapid qualitative analysis for broad themes, then
framework analysis mapped to the COM-B Model to understand PHP
behaviours.
Results: 10 interviews have been completed so far. Following rapid qualitative
analysis, themes that inﬂuence referral include patient characteristics, age,
employment status, disease variability and severity, PHP knowledge and
understanding of PR. PHP combine these elements and independently assess
likely PR engagement using a patient beneﬁt vs loss assessment, creating PHP
internal conﬂict. External inﬂuencing factors include poor marketing, lack of
incentive and PR programme variability. PR is not seen as a core intervention
within the management of COPD highlighting a whole systems inﬂuence.
Conclusions: PHPs, PR providers and whole systems are important in
inﬂuencing the referral to PR. PR providers must promote the service better.
PHPs must discuss PR and work in partnership with COPD patients.
Conﬂicts of Interest: Trustee - PCRS-UK, nil else of note.
Funding: Sponsor by University of Birmingham.
Corresponding author: Jane Young.
Email: jane.young@anglia.ac.uk
S21. Professional and staff perceptions of ﬁnancial incentives
promoting implementation of asthma self-management: a
qualitative study in Northern Ireland primary care practices
T Jackson, L Heaney, M Shields, M Kendall, H Pinnock
Asthma UK Centre for Applied Research, Usher Institute of Population Health
Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
Background: In 2008, Northern Ireland introduced a healthcare scheme that
pays a ﬁnancial incentive to general practices for providing self-management
education to patients with asthma.
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Aim: We aimed to explore how primary care practices responded to the
ﬁnancial incentive scheme, their strategies for achieving the required
standards, and the impact on implementation of asthma self-management,
including provision of asthma action plans.
Methods: We aimed to recruit up to 20 general practices across Northern
Ireland and undertake a telephone interview with a representative from each
practice involved with delivering the scheme. An incentives framework was
used to underpin questions in the interviews, which were recorded,
transcribed verbatim and analysed using a Grounded Theory approach.
Results: Interviews have been conducted with 12 practice staff members
involved with the ﬁnancial incentive scheme within their practice (1 GP, 2
nurses and 9 administrative staff). Themes clustered around targeting poor
asthma control; communicating with patients; strategies for achieving targets;
ﬁnancial incentives. All participants highlighted the difﬁculty of getting
patients with asthma to attend appointments, with some expressing feelings
of frustration at lack of patient involvement. Developing processes and
strategies to increase attendance for patients with asthma was discussed in
the majority of interviews, with a number of participants speciﬁcally targeting
patients with poorly controlled asthma. Participants were generally positive
about receiving ﬁnancial incentives for the extra work undertaken, but the
main motivator was to provide the best quality of care for patients.
Conclusions: Primary care practice staff view ﬁnancial incentives positively;
however, patient health was the highest priority when delivering care.
Practices are continually developing strategies to increase patient attendance
for annual reviews, particularly among those with poorly controlled asthma.
Understanding how practices responded to this ﬁnancial incentive scheme
could inform future policy on similar initiatives.
Conﬂicts of Interest: None.
Funding: This work is funded by The University of Edinburgh, College of
Medicine and Veterinary Medicine (CMVM) PhD Studentship [Asthma UK
Centre for Applied Research PHD/14/16].
Corresponding author: Tracy Jackson.
Email: tracy.jackson@ed.ac.uk
S22. Investigating asthma comorbidities: a systematic scoping
review
K El Ferkh, E Vasilieou, BI Nwaru, C Weir, C Grifﬁths, A Sheikh
University of Edinburgh, Edinburgh, UK
Aim: Asthma is a common long-term disorder with several related comorbid
conditions, which may impact asthma outcomes. There is a need for greater
appreciation for understanding how these comorbidities interact with asthma
to improve asthma outcomes. The aim of this study was to systematically
scope and map out the range and nature of key asthma comorbidities.
Methods: We systematically searched the following electronic databases for all
research relating to comorbidities in people with asthma: Medline, EMBASE, ISI
Web of Science, Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PsycINFO, and Google Scholar.
Results: We identiﬁed 10,888 studies through our literature search of which
only 23 studies fulﬁlled our predeﬁned inclusion criteria. We found evidence of
a lack of uniform way of deﬁning and measuring comorbidity. Much of the
available literature was around prevalence of comorbidities among people
with asthma. Less is known about how these comorbidities vary by age or
gender, and how these affect asthma outcomes and prognosis.
Conclusion: The prevalence of comorbidities in asthmatics is high. Although
additional studies are needed to clarify the concept of deﬁning and measuring
comorbidities, the evidence from our systematic scoping review provides a
comprehensive overview of asthma comorbidities. There is a need for more
research looking at the mechanisms and pathological pathways of
comorbidities on asthma outcomes.
Conﬂicts of Interest: None.
Funding: Asthma UK Centre for Applied Research (AUKCAR); Chief Scientist
Ofﬁce (CSO).
Corresponding author: Karim El Ferkh.
Email: k.ﬁrikh@ed.ac.uk
Acknowledgment: It has been presented at IPCRG 2017 Slovenia.
S23. Use of soft mist inhalers versus dry powder inhalers in
patients with chronic obstructive pulmonary disease (COPD): a
Clinical Practice Research Datalink (CPRD) study
A Gayle, A Tebboth, G Chiu
Boehringer Ingelheim Ltd, Bracknell, UK
Aim: Long-acting muscarinic antagonists (LAMA) are available in different
inhaler devices for patients with chronic obstructive pulmonary disease
(COPD), dry powder inhalers (DPI) or soft mist inhalers (SMI), of which DPI are
the most commonly prescribed. The Respimats device (launched 2007) is the
only commercially available SMI. We studied the demographic and clinical
characteristics of patients newly initiating LAMA in either DPI or SMI, to
determine if patient characteristics affect prescribing of these devices.
Method: This was a retrospective study analysing primary care data from the
UK Clinical Practice Research Datalink (CPRD). The patient cohort included
people with a prior diagnosis of COPD registered at their GP practice from
January 2008 to December 2015. The demographic and clinical characteristics
of patients at either ﬁrst initiation of a DPI or an SMI were compared.
Results: 30,635 patients met the inclusion criteria and were studied. The
average age was 67.5 years and 54% were male. The majority (90%) of patients
were in the DPI group. There were no signiﬁcant differences between the
groups in either age, smoking status, body mass index or the following co-
morbidities: myocardial infarction, cerebrovascular disease, cancer, stroke,
eosinophilia, peripheral vascular disease or renal impairment. Small differences
(Po0.05) were observed in the following characteristics: severe airﬂow
limitation (21% vs. 23% DPI vs. SMI respectively); GOLD stage B (33% vs. 37%);
historic/concurrent asthma (9% vs. 10%); atrial ﬁbrillation (7% vs. 6%);
congestive heart disease (14% vs 13%); diabetes (11% vs. 10%). Annual
differences in SMI initiations (14% in 2010 to 4% in 2016) were observed, as
were regional differences in DPI prescription (83% in South Central England to
98% in North East England).
Conclusions: Patient characteristics do not appear to have a meaningful impact
on the choice of DPI vs. SMI. This is consistent with recommendations in the
relevant summaries of product characteristics.
Conﬂicts of Interest: AG, AT and GC are employees of Boehringer Ingelheim Ltd.
Funding: This study was funded by Boehringer Ingelheim Ltd.
Corresponding author: Alicia Tebboth.
Email: alicia.gayle@boehringer-ingelheim.com
S25. How to secure better outcomes for everybody in asthma
management: The International–Medicines Use Review Health
Technology Assessment (International-MUR HTA)
Michela Tinelli1, Andrea Manfrin2
1Personal Social Services Research Unit, Department of Health Policy, The London
School of Economics and Political Science; 2Medway School of Pharmacy,
University of Kent
Aims: This project is looking at the development and application of the novel
tool (International–Medicines-Use-Review-Health-Technology-Assessment;
International-MUR HTA) in community practice that for the ﬁrst time is able
to meet better asthma control and secure added value service in asthma
management. More speciﬁcally it allows to: evaluate the quality of care
delivered in terms of economic impact (for patient-provider-society), health
outcomes and patient beneﬁts; collect real-world evidence and evaluate long-
term effect of care; provide different stakeholders with evidence-based
information that would help formulate health policies in community practice
that are safe, effective, patient-focused and cost-effective, balancing access to
innovation and cost containment. Crucially, the tool can also support the
delivery of a cost-effective and cost-saving intervention for asthma patients
based on the success of the Italian-Medicines-Use-Review (I-MUR) trial [1].
Methods: Evidence from the Italian-Medicine-Use-Review (I-MUR) trial showed
that the I-MUR intervention provided by the community pharmacists in
asthma is effective, cost-saving and cost-effective.1 The trial allowed to model
a novel framework (International-MUR-HTA) that would enable to routinely
deliver the intervention, but also collect and analyse patient relevant data on
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its clinical-effectiveness, quality-of-life and cost-effectiveness. I-MUR-HTA was
discussed within three expert-panel discussions including policy-makers,
commissioners, academics, healthcare-professionals and patient-
representatives in Italy,2 UK3 and Brussels/Europe.4 The current plan
includes testing the use of the tool in RW environment across European
regions.
Results: Evidence collected from the expert discussions conﬁrmed that
International-MUR-HTA information is relevant to meet current NICE target
for cost-effective service delivery and this is what is needed to support the
evaluation of innovative effective and cost-effective health policies and
promote their implementation across nations. Its implementation is underway
and real-world pilots are planned to take place in different European regions.
Conclusion: the International-MUR-HTA appears to be an innovative tool to
promote active patient involvement into policy-decision-making and com-
munity service implementation.
Conﬂicts of Interest: None.
Funding: We are grateful to the Italian Pharmacists’ Federation (FOFI) who
funded the C-RCT and J Krska and T Thomas for their contribution to the
C-RCT. The authors thank the Italian pharmacists, general practitioners and
consultants, patients and all other people who have been involved in the
C-RCT. Special thanks go to John White who reviewed the output of the tool
looking at its applicability in the clinical setting.
Corresponding author: Michela Tinelli.
Email: m.tinelli@lse.ac.uk
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S27. Assessing technology-assisted asthma administration in
enhancing inhalation and prescription compliance
J O’Kelly, J Harkin, L McDaid
Aberfoyle Medical Practice, 120 Strand Road, Derry City, Northern Ireland BT48
7NY, UK
Asthma is highly prevalent in children and adolescents, and inhaled anti-
inﬂammatory agents are a mainstay of treatments. However, compliance
amongst children and adolescents is low with poor inhaler usage and
inhalation technique. Spacer devices attached to metered dose inhalers (MDI)
can assist in drug delivery. Recently, SmartAir Medical Ltd. (based at the Clinical
Translational Research and Innovation Centre in Londonderry, Northern
Ireland) developed AIRBRIO, an electronic product for patients who use a
spacer-MDI combination that can record compliance data and relay it to a
smartphone. This abstract investigates the use of the example technology,
AIRBRIO, in enhancing inhalation and prescription compliance. A pilot study
was undertaken with 29 participants (step II or III asthma) and were aged 8 to
18 (half had attended Accident and Emergency (A&E) or been admitted to
hospital owing to their asthma condition in the past). At baseline, participants
completed asthma control questionnaires, underwent lung function testing
and received instruction on the use of AIRBRIO. These measures were repeated
at the end of the 8-week study with opinions on AIRBRIO provided. In 43% of
participants, spirometry readings improved signiﬁcantly in 2% predicted results
over the course of the study with percentage increase change for forced
expiratory volume 1 (FEV1) % predicted = 5.0% and forced vital capacity (FVC)
% predicted= 5.5% (Po0.001). In addition, 78% reported that they ‘always’/
‘most of the time’ used a spacer when taking their inhaler compared to 45%
baseline Care of the spacer improved with 82% washing it at least once a
month. While the results from this study warrants a further larger-scale study,
its note that over 80% were in total agreement that it taught them how to
inhale their medication better, with 65% ‘very strongly agreeing’ that it had
improved their inhalation technique. In summary, the study found that
AIRBRIO improves inhalation and prescription compliance and may therefore
prove useful as a tool in the management of asthma and chronic obstructive
pulmonary disease (COPD).
Conﬂicts of Interest: None.
Funding: The Northern Ireland Department of Health, Social Services and Public
Safety (DHSSPSNI) in partnership with Technology Strategy Board, working
with the Northern Ireland Department of Enterprise, Trade and Investment
(DETI) and Invest Northern Ireland (InvestNI).
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S28. Endotypes of chronic obstructive pulmonary disease
(COPD): their role in determining response to inhaled
corticosteroids
TH Harries, C Corrigan, PT White
King's College London, King's Health Partners, Division of Health and Social Care
Research, London, UK
Aim: To identify the endotypes of chronic obstructive pulmonary disease
(COPD) which may be predictive of treatment response to inhaled
corticosteroids. Endotypes are disease subtypes deﬁned by a distinct
functional or pathophysiological mechanism.
Method: We conducted a scoping literature review to investigate the
predictive value of endotypes in the treatment of COPD with inhaled
corticosteroids. The deﬁnition and application of endotypes in COPD made a
systematic review impractical. We searched the Pubmed index for all articles
including the terms “COPD endotypes” & “COPD endotype” & “COPD
endotypes and phenotypes”.
Results: We found 32 articles which referred to COPD endotypes. Ten articles
discussed the relationship between endotype and phenotype and its
relevance to treatment decisions. Six review articles described speciﬁc
endotypes of COPD. Five endotypes of COPD, and their respective biomarkers,
were most frequently proposed. These were the T-Helper 2 (TH2) inﬂammatory
response endotype (serum/sputum eosinophilia, fractional exhaled nitric oxide
(FeNO), perisotin, immunoglobulin E (IgE), cytokines interleukin (IL) 4, IL-5,
IL-13), the persistent systemic inﬂammation endotype (C-reactive protien
[CRP], ﬁbrinogen, cytokines IL-6, IL-8), the bacterial colonisation of the airways
endotype (sputum culture), the neutrophilic endotype (cytokine IL-8)
and the Alpha-1 antitrypsin deﬁciency endotype (α1AT genotyping). Of these,
the TH2 inﬂammatory response endotype represents an opportunity
to deﬁne a subgroup of patients with COPD who show steroid
responsiveness.
Conclusion: Deﬁning COPD endotypes may improve our understanding of the
underlying pathophysiology of COPD and lead to more rational approaches to
prescribing of inhaled corticosteroids. Progress in identifying reliable and
accessible biomarkers of these endotypes should improve targeted treatment
of COPD patients.
Conﬂicts of Interest: None.
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Corresponding author: Timothy Harries.
Email: timothy.harries@kcl.ac.uk
S31. Examining licensed and unlicensed spacer use with non-
extraﬁne beclometasone dipropionate treatment in a real-life
patient population with asthma in the United Kingdom
S Wan Yau Ming, S Patel, M Ochel, SI Thornhill, DB Price
Observational and Pragmatic Research Institute, Singapore
Aim: Spacer devices reduce dependency on correct inhaler technique. Asthma
management guidelines recommend spacers for use with pressured metered
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dose inhalers for patients prescribed high dose inhaled corticosteroids (ICS)[1]
and children o16 years[H. The aim of this study was to assess spacer co-
prescription and device-type in a real-life population of patients with asthma
treated with non-extraﬁne (non-EF) beclometasone dipropionate (BDP), in
groups where spacers are recommended.
Method: A cross-sectional study using data extracted from the Optimum
Patient Care Research Database. Patients were characterised over a 1-year
study period prior to the date of medical records extraction. Spacer co-
prescription with non-EF BDP was considered if within 1 year. Patients with
asthma, aged ≤ 65 years, with ≥ 2 prescriptions for non-EF BDP were studied.
Patients were categorised by age (o16, 16–65 years) and ICS dose
(o1,000 μg/day vs ≥ 1,000 μg/day). Spacers studied included the licensed
Volumatics and unlicensed Ables, Aerochambers, Pocket Spacers, generic
and ‘other’ branded devices.
Results: 50,467 patients were studied, mean age 41 years, 70.2% of whom were
not co-prescribed a spacer. Of the total population prescribed spacers (29.8%),
the most commonly prescribed were the unlicensed Aerochambers
(59.0%) followed by the licensed Volumatics (20.5%) and ‘other’ branded
unlicensed spacers (10.5%). 71.1% of patients on high-dose non-EF BDP
(n= 3,126) were not co-prescribed a spacer; for the 28.9% co-prescribed a
device, 55.2% had an Aerochambers, 26.0% a Volumatics and 8.4% ‘other’
spacers. 45.9% of the 12,883 patients aged o16 years received a spacer; the
Aerochambers (55.9%) and Volumatics (18.9%) devices were most
commonly prescribed.
Conclusion: In real-life practice, despite being unlicensed, the Aerochambers
spacer is most commonly prescribed with non-EF BDP, ahead of the licensed
Volumatics device. Co-prescription of spacers, as recommended by guide-
lines, is not followed for the majority of patients.
[1] National Institute for Clinical Excellence Asthma Guidelines 2002.
[2] HBTS/SIGN Asthma Guideline 2016.
Conﬂicts of Interest: Dr S Wan Yau Ming and Dr SI Thornhill are employees of
the Observational & Pragmatic Research Institute (OPRI). Observational and
Pragmatic Research Institute Pte Ltd conducted this study with funding from
Chiesi and has conducted paid research in respira.
Funding: This study was funded by Chiesi UK.
Corresponding author: Simon Wan Yau Ming.
Email: simon@opri.sg
S32. Teleconsultation sleep clinic review in Dumfries and
Galloway—a patient acceptability survey
Phyllis Murphie, Jenny Carlsson, Robin Paton, Stuart Little
Respiratory Medicine Department, National Health Service (NHS) Dumfries and
Galloway, Dumfries, DG14AP, UK
Aim: To assess patient acceptability and experience of teleconsultation
review in people with obstructive sleep apnoea hypopnoea syndrome
(OSAHS) who are using continuous positive airway pressure (CPAP) therapy,
and to quantify any efﬁciency savings in terms of reduction in mileage
traveled for patients and clinical staff, fuel consumption and reduction in
carbon footprint impact.
Methods: 120 service users diagnosed with OSAHS who were utilising CPAP
therapy were asked to complete a postal survey regarding their experience
and views of remote teleconsultation in May 2017.
Results: 50 people returned completed surveys, representing a 42% response
rate. The majority of respondents rated their teleconsultation review as
satisfactory with only one person disliking this approach, and preferring the
standard clinic follow-up. The reduction in distance traveled for the service
users equated to a saving of 7,000 miles and 1,700 miles for clinical staff, with
approximately 2.62 tonnes in reduced carbon emissions. The reduction in
clinical staff travelling time equated to 42 h.
Conclusion: Our results demonstrate that teleconsultation is very acceptable to
the vast majority of service users who received this intervention and there are
signiﬁcant departmental ﬁnancial beneﬁts and environmental economies for
sleep medicine healthcare providers. The time saved by clinicians not
travelling to distant clinic sites can be reinvested in other service areas. We
now offer this method of clinical review as part of our mainstream service and
are looking ahead at home teleconsultation possibilities using current
technology. Delivered at scale this method of clinical review can offer
signiﬁcant ﬁnancial savings for the National Health Service (NHS) and we
would encourage other Sleep medicine providers to explore the use of
teleconsultation in their service.
Conﬂicts of Interest: none.
Funding: none.
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S33. Investigation health related quality of life adult patients
with asthma
E Stamatopoulou1, A Christodouli Brinia2, A Stamatopoulou3,
N Kontodimopoulos4
1M.Sc. National School of Public Health, Nursing Αnesthesiology Department
General Hospital KAT, Educational National Instant Emergency Aid Centre Ministry
of Health and Institutes Professional Training Ministry of Education, Research and
Religious Affairs; M.Sc. Master of Science in Management of Health and Social
Welfare Services Piraeus University of Applied Sciences, Greece; European University
Cyprus, Athens, Greece; Member PCRS UK; 2MD, MSc Hellenic Open University
Health Care Management; Allergologist, Director of Public Health Management
Achaia, Patras, Greece; 3Economist; M.Sc. International Human Resourse
Management; M.Sc. Master of Science in Management of Health and Social
Welfare Services Piraeus University of Applied Sciences, Greece & European
University Cyprus; Support for Teaching Project Piraeus University of Applied
Sciences, Greece; 4PhD Hellenic Open University in Management and Economics of
Health, Member Associate Educational Personnel Hellenic Open University,
Director General Hospital of Attica ‘KAT’ and National Rehabilitation Center
‘ΕΚΑ’ Athens, Greece
Aim: To assess health related quality of life (HRQoL) of adult patients with
asthma using generic and disease-speciﬁc questionnaires, to identify the
factors (atopy, severity, smoking, therapy, immunotherapy) that affects it, the
comparison with other studies and ﬁnally the comparative evaluation of the
questionnaires themselves.
Methods: HRQoL was assessed using the Asthma Control Questionnaire (ACQ),
Asthma Quality of Life Questionnaire (AQLQ), short form (SF)-36 and Euroqol
(EQ)-5D questionnaires in 104 adult asthma patients. The study was held in the
Allergy Department at Laiko Athens General Hospital.
Results: Asthma is a chronic disease that affects 300 million patients
worldwide. It is usually characterized by chronic airway inﬂammation and is
deﬁned by the history of respiratory symptoms such as wheezing, shortness
of breath, chest tightness and cough. Asthma is a serious challenge to
public health and has large effects on school and work performance of
patients, as well as in use of hospital emergency services. Patients with
allergic asthma and more speciﬁcally those who were under immunother-
apy treatment had higher HRQoL. Asthma severity affected negatively
HRQoL in all questionnaires, but it affected only Mean SF-36 Physical
Component Summary and had no impact on the mental component score
(MCS). Smοking had not statistical correlation with HRQoL. Obesity (higher
body mass index [ΒΜΙ]) affected negatively HRQoL in only some subscales of
the questionnaires concerning physical activity. Finally there is a signiﬁcant
correlation between the speciﬁc ACQ and AQLQ and the generic SF36 and
EQ5D questionnaires.
Conclusions: Measuring asthma HRQoL in addition to standard clinical
parameters in clinical medical practice using speciﬁc and generic ques-
tionnaires, would provide useful details that could improve patient’s everyday
life. Using them on patients with different asthma phenotypes and endotypes
would help to better evaluate and validate the results.
Conﬂicts of Interest: none.
Funding: none.
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S34. A qualitative study on the use of electronic alerts to
identify excessive prescribing of short acting beta2-agonist
(SABA) inhalers in people with asthma: the views of asthma
experts and primary care staff
S McKibben, A Bush, M Thomas, C Grifﬁths
Asthma UK Centre for Applied Research, Queen Mary University London
Aim: The National Review of Asthma Deaths (NRAD) highlighted that 39% of
people with asthma who had died were prescribed more that 12 short acting
beta2-agonist inhalers (SABA) in the year before death, with 4% prescribed
more than 50.1 NRAD recommended the electronic surveillance of SABA to
alert clinicians to excessive SABA prescribing,1 with those prescribed more
than 12 SABA in the previous 12 months brought to the clinician’s attention
and invited for urgent review of their asthma control.1,2 In this study we aimed
to determine the type of alert system that general practice teams want, and
would use, to identify excessive SABA use in primary care.
Method: Qualitative research purposefully sampled 33 participants including
asthma experts (13), general practitioners (9), nurses (2), receptionists (7) and
pharmacists (2). Semi-structured interviews (in-person and telephone), a
discussion group and observations were carried out. Data were digitally
recorded and/or observational notes taken. Thematic analysis is on going.
Results: Emergent themes have shed light on the design and usability of alerts
to identify high SABA prescribing in primary care. Four initial themes have
emerged: methods to identify high SABA use; the repeat prescribing process
for SABA; the challenge of identifying and managing high SABA use; how
these challenges could be overcome. Alerts to identify high SABA use have
been positively welcomed however many challenges exist, for example in
determining who alerts should target, when they should present and the
appropriate action to be taken. End users should be considered in system
design and implementation to increase usability and improve asthma
management.
Conclusion: Findings will inform the development of an alert system to identify
patients prescribed high numbers of SABAs in primary care.
1. Royal College of Physicians. Why Asthma Still Kills-The National Review of
Asthma Deaths (NRAD) Conﬁdential Enquiry report (2014).
2. British Thoracic Society and Scottish Intercollegiate Guidelines Network.
British guideline on the management of asthma (2016).
Conﬂicts of Interest: none.
Funding: Queen Mary University of London/Asthma UK Centre for Applied
Research.
Corresponding author: Shauna McKibben.
Email: s.m.mckibben@qmul.ac.uk
S35. Are chronic obstructive pulmonary disease (COPD)
outcomes different in patients who have also been diagnosed
with anxiety and/or depression: a real-life UK cohort study
EL Ray, D Culliford, L Joseph, M Johnson, DM Thomas
University of Southampton, Southampton, England
Aim: To assess whether those also diagnosed with anxiety and/or depression
within a UK primary care chronic obstructive pulmonary disease (COPD)
cohort have different outcomes and demographic characteristics compared to
those without.
Method: A retrospective observational study using individual patient-
anonymised routine data in the Hampshire Health Record Analytical Database,
which contained linked primary and secondary care clinical data for around 1.4
million patients in Hampshire, UK.
Clinical terms (Read codes) were used to identify a cohort with prevalent
COPD as at 31/12/2010. Patients were categorised by smoking status, age, sex
and body mass index (BMI) and by a range of comorbid conditions, including
psychological disorders such as anxiety and depression.
All respiratory-cause unplanned hospital admissions and respiratory-cause
Accident and Emergency department (A+E) attendances were the outcomes
recorded over a 3-year period (2011–13).
Survival analysis and cox regression was used to estimate hazard ratios (HR) for
each outcome, adjusting for potential confounders and testing for interactions
between psychological distress (anxiety and/or depression) and the main
demographic variables.
Results: Of a total of 16479 COPD patients (53.7% men, mean age 70.1 years),
6,392 (38.8%) also had a diagnosis of a psychological disorder at some time in
the medical record.
Adjusting for confounding factors (age, gender, smoking status, BMI, forced
expiratory volume 1 (FEV1) % predicted, FEV1/FEV ratio, presence of
comorbidities), it was observed that in COPD patients with co-existing anxiety
and/or depression there was an increased incidence of attendance at A&E (HR
1.47, 95% CI = 1.30–1.67, Po0.001) and admission to hospital (HR 1.26, 95%
CI = 1.15–1.38, Po0.001).
Conclusion: Over one third (38.8%) of all patients diagnosed with COPD in a
large primary care cohort also had a diagnosis of anxiety and/or depression
documented in their medical history. The presence of anxiety and/or
depression signiﬁcantly increased the likelihood of attendance at A+E and
admission to hospital, even after adjusting for potential confounders.
Conﬂicts of Interest: none.
Funding: Funding for the project was provided by the Collaboration for
Leadership and Applied Health Research and Care (CLAHRC) Wessex.
Corresponding author: Emma Ray.
Email: emma.ray@uhs.nhs.uk
S36. The relationship between anxiety and quality of life in
patients with asthma: ﬁndings from the Breathing REtraining for
Asthma Trial of Home Exercise (BREATHE) trial
Ben Ainsworth, Samuel Mills, Anne Bruton, Mike Thomas
Primary Care & Population Sciences, University of Southampton, UK
Aim: The mechanisms behind breathing retraining for asthma are unknown,
but this therapy may affect psychological dysfunction, independently to any
lung function improvement.1 Recent calls have emphasised the importance of
understanding how psychological/behavioural mechanisms impact upon
asthma outcomes.2 We explored the importance of anxiety in relation to
outcomes for the Breathing REtraining for Asthma Trial of Home Exercise
(BREATHE) trial.3
Method: 655 primary care patients with asthma (64% female, mean(SD) age:
53.1(13.6); forced expiratory volume 1 (FEV1): 91(20)% predicted; FEV1/forced
vital capacity (FVC): 0.7) completed a face-to-face (N= 261) or DVD-based
(N= 132) self-guided breathing retraining intervention vs. usual care (N= 262).
Participants completed self-report questionnaires of anxiety/depression
(HADS), quality of life (AQLQ), asthma control (ACQ), dysfunctional breathing
(Nijmegen) and lung function measures at baseline, three-, six- and 12-month
follow-up.
Results: Stepwise linear regression (including age, gender, asthma control,
anxiety, depression, dysfunctional breathing, FEV1/FVC) found improved
asthma control (t= 4.71) and anxiety (t= 3.65) to predict improved quality of
life (B= 5.18, SE = 0.06, t= 93.3, Po0.001) across all patients.
Repeated-measures analysis of covarience (ANCOVA) of asthma-related
quality of life from 0-12 months found an interaction between time and
treatment arm [F= 5.14, P= 0.006], subsumed by an interaction with high vs
low anxiety, [F= 3.57, P= 0.03]. Quality of life improved in breathing retraining
vs. control in patients with high baseline anxiety (mean difference= 0.46,
F= 12.3, Po0.001) but not in patients with low anxiety (diff = 0.12, F= 0.9,
P= 0.33).
Conclusion: Our ﬁndings suggest that non-pharmacological treatments like
breathing retraining may improve quality of life by reducing anxiety. Future
research should explore how treatments can be personalised for people with
high anxiety to maximise effectiveness.
Conﬂicts of Interest: none declared.
Funding: The BREATHE project was funded by an National Institute for
Health Research (NIHR) Health Technology Assessment 09/104/19. BA is
funded by an NIHR Post-doctoral Translational Fellowship (School of
Primary Care).
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S39. The development and implementation of a personal health
organiser for patients diagnosed with idiopathic pulmonary
ﬁbrosis (IPF): a pilot study
Owen J Dempsey, Ian Forrest, Catherine Bamlett, Claire Donaldson,
Ruth Sabella, Ashley Green, AM Russell
Consultant Respiratory Physician and Service Lead Aberdeen Royal Inﬁrmary,
Aberdeen, Scotland, UK
Background: The British Lung Foundation (BLF) advocates for supported self-
management approaches. There were no patient-held-records or personal
healthcare organiser (PHO) initiatives for people with Idiopathic Pulmonary
Fibrosis (IPF) in 2014. We proposed to develop, test and evaluate a PHO
adapting models employed by Diabetes UK and Macmillan.
Methods: The structure, format and content was informed by patients and
Interstitial Lung Disease (ILD) healthcare professionals; cross referenced by The
National Institute for Health Care Excellence (NICE) guidelines and British Lung
Foundation (BLF) resources. Participants completed a hard copy of the PHO
over 6 months. Pre-study and 2 weeks post-study, a 13-item questionnaire to
assess knowledge and conﬁdence in managing IPF was completed.
Participants afﬁrmed level of agreement on a 5-point Likert scale
(scores 0-4). Post-study focus groups (FG’s) were held, one at each of the
recruiting specialist centres. The FG sought to evaluate patients’ perceptions of
the usefulness of the PHO as an adjunct to the medical record and as an aid to
self-management.
Results: Twenty-nine patients completed pre-pilot questionnaires. Ages o60
years = 3; ≥ 60 years = 9; ≥ 70 years = 7;≥ 80 years = 9. Two participants
had been diagnosed with IPF within 6 months; seven o2 years ago and
eighteen 42 years. Seven patients died before the PHO phase.
Twenty patients completed the PHO. 60% male. Mean % predicted
forced vital capacity (FVC) 70.75 ± 15.7. Thirteen patients and seven family
members participated in FG’s. Mean change between pre and post study
questionnaire is 5.65. Median score changes were noted for two ‘conﬁdence’
items relating to self-management of medication and solution-focused-
thinking for new health problems. This supports themes identiﬁed in FG
transcript analysis.
Outcomes: The IPF PHO was to easy understand and used regularly by two
thirds of participants. It contributed to increasing knowledge, skills and
conﬁdence, further supporting self-management. Patients shared the PHO
with nurses and hospital doctors who perceived it helped to facilitate
discussion. Participants rarely used the PHO in GP consultations which requires
further exploration.
Conﬂicts of Interest: None.
Funding: British Lung Foundation.
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S41. Rhythm & song: breath management in idiopathic
interstitial pneumonias (IIP). Pilot study
P Cave, K Taylor, A Lewis, NS Hopkinson, AU Wells, AM Russell
Music Therapist, Vocal Coach, Consultant & Project Manager in Music & Health
Royal Brompton and Hareﬁeld National Health Service (NHS) foundation Trust
Introduction: Breathlessness is a distressing symptom. Current therapies offer
little relief in Idiopathic Interstitial Pneumonias (IIP). Breathlessness manage-
ment utilising techniques for breathing control, mindfulness and posture,
speciﬁcally tailored to IIP may be helpful.
Methodology: Participants attended a 12 week programme. Weekly sessions
were based on concepts of Singing for Breathing1 using physical and vocal
warm-ups; breathing exercises; rhythm / pitch games; songs and relaxation.
Participants completed a diary recording reﬂective, retrospective thoughts
before and immediate responses after each class. The music therapist
completed a weekly reﬂective diary. Later sessions were audio recorded.
Measures of symptom burden were completed at weeks 1 and 12.
Results: Ten participants, 7 male; mean age 72 (range 64-81 years) enrolled.
Participants completed questionnaires and forced vital capacity (FVC) was
recorded at week one and week twelve. There were improvements in mean
scores from week one to week twelve in depression Patient Health
Questionnaire (PHQ)-9: 4.5 (±3.12) to 3.8 (±3); anxiety Generalized Anxiety
Disorder (GAD)-7: 2.11 (±2.42) to 1.60 (±1.67); quality of life St. George’s
Respiratory Questionnaire (SGRQ) Symptoms: 55.60 (±29.39) to 48.60 (±26.83);
SGRQ Activity: 58.38 (±30.49) to 51.23 (±41.06); SGRQ Impacts: 33.71 (±22.58) to
19.98 (±12.81) and SQRQ Total 43.97 (±28.00) to 30.18 (±20.64). Perceptions of
breathlessness improved according to modiﬁed Medical Research Council
(mMRC) scale. There was no meaningful change FVC. Emotional Thermo-
meters Visual analogue Scale demonstrated a reduced need for help at the
end of the 12 week programme. Diaries were subjected to thematic analysis;
the following themes were identiﬁed: Physical experience; psychological
wellbeing; cognitive ability and social functioning. Participants agreed the
course was a positive experience physically, emotionally and socially offering
skills for better symptom management.
Discussion: The study provides a positive baseline for which to plan and
continue future work. A larger multicentre centre study is needed to conﬁrm
these ﬁndings in a larger population integrating a robust end point model.
Conﬂicts of Interest: None.
Funding: This work is was supported by a British Lung Foundation grant: RG-16-20.
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